01:51:45 EDT Sun 19 May 2024
Enter Symbol
or Name
USA
CA



Ventripoint Diagnostics Ltd (2)
Symbol VPT
Shares Issued 157,023,905
Close 2024-02-01 C$ 0.26
Market Cap C$ 40,826,215
Recent Sedar Documents

Ventripoint provides VMS+ to Medical University Vienna

2024-02-01 11:59 ET - News Release

Dr. Alvira Macanovic reports

THE MEDICAL UNIVERSITY OF VIENNA'S PAEDIATRIC HEART CENTRE PURCHASES VENTRIPOINT'S AI-POWERED HEART IMAGING SYSTEM

The Paediatric Heart Centre at the Medical University of Vienna has chosen to adopt Ventripoint Diagnostics Ltd.'s VMS+ as its cardiac diagnostic tool.

The pediatric cardiology department is part of the Children's Heart Centre Vienna and is the oldest pediatric cardiology department in Austria. The core unit is the department of pediatric cardiology, located at the University Hospital for Children and Adolescent Medicine.

"We are very excited to be partnering with this world-renowned hospital to bring our technology to the doctors and patients at The Paediatric Heart Centre cardiac-care programs," said Dr. Alvira Macanovic, Ventripoint's chief executive officer and president. "This continues our strategy of placing our VMS+ diagnostic units, which offer a cost-effective alternative to cardiac MRIs [magnetic resonance imaging], in leading hospitals around the world."

Using the VMS+, caregivers at the pediatric cardiology department can use ultrasound images to create detailed heart scans in minutes at a fraction of the costs of MRIs. The pediatric cardiology department provides world-renowned care for children with heart disease and is widely recognized for having industry leaders as its main care providers.

Ventripoint is committed to improving patient care through innovative technologies like the VMS+, and will continue to bring its artificial intelligence-powered diagnostic technologies to health care professionals and institutions.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of artificial intelligence to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide its future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.